In the wake of a recent New York Times investigation into alleged misuse of 340B savings by Catholic health system Bon Secours Mercy in Richmond, Va., a local Richmond newspaper has published a comprehensive look at the purpose and value
…
Articles by : Ted Slafsky, Publisher & CEO
Breaking News
Exclusive: HHS OIG Declines to Penalize Drug Manufacturers at This Time Over 340B Contract Pharmacy Restrictions
The U.S. Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers that have
…
In a big victory for 340B hospitals, a federal judge in Washington, D.C. ruled yesterday that the government must immediately begin to pay 340B hospitals the full Medicare Part B drug payment rate for the remainder of calendar year (CY)
…
Shockwaves from the New York Times’ investigative piece on the alleged misuse of 340B savings by a Catholic health system in Richmond, Virginia continues to spread, as local news outlets and government leaders from all levels respond. The lengthy article
…
Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff
…
Walgreens Boots Alliance (WBA) announced September 20th that it is acquiring the remaining 30% stake in 340B specialty pharmacy company Shields Health Solutions that it did not already own. WBA first invested in Shields in July 2019. Last year, it spent
…
Elise Stefanik (R-N.Y.), U.S. congresswoman for the 21st district in upstate New York and third highest-ranking Republican in the House of Representatives, visited independently-owned Condo Pharmacy in Plattsburgh, N.Y., last week in a show of support for the 340B contract pharmacy
…
The Government Accountability Office (GAO), Congress’s watchdog agency, is conducting a study of a new law that enables hospitals to maintain or regain their 340B eligibility despite having fallen below the minimum required Medicare disproportionate share (DSH) adjustment percentage due
…
The U.S. Office of Pharmacy Affairs (OPA), the department within the U.S Health and Resources Administration that oversees the 340B program, would receive a $2 million increase in funding under a bill that passed through a major House committee last
…
With more than six months to go in the year, the number of refunds that drug manufacturers have had to provide to 340B providers has already topped the previous annual record of 17. Drug manufacturer Novo Nordisk becomes the 21st manufacturer to